Cambridge, UK, September 10-13, 2023 Vipergen presents a poster entitled: Efficient Cell-Based DEL Screening https://www.soci.org/events/fine-chemicals-group/2023/sci–rsc-22nd-medicinal-chemistry-symposium
SCI/RSC 22nd Medicinal Chemistry Symposium Read More »
Zagreb, Croatioa, September 3-7, 2023 Vipergen presents a poster entitled: Efficient Cell-Based DEL Screening https://www.efmc-asmc.org/
IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry Read More »
Cambridge, US, November 1-2, 2023 Vipergen gives a talk entitled DELs in Cells https://www.oxfordglobal.co.uk/discovery-us/
Cambridge, MA. 3-4 November, 2022. Vipergen gives a talk Entitled: DELs in Cells. https://www.delsymposium.org/program
10TH INTERNATIONAL SYMPOSIUM ON DNA-ENCODED CHEMICAL LIBRARIES Read More »
Berlin, Germany 6-7 June, 2023 Vipergen gives a talk entitled: DELs in Cells https://www.oxfordglobal.co.uk/discovery-series/
Discovery Europe 2023 Read More »
London ,UK, 2-3 Mar, 2023. Vipergen gives a talk entitled: DEL Screening Inside Living Cells.
Ace Drug Discovery Summit (ADDS 2023) Read More »
COPENHAGEN, Denmark, June 15, 2022—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new
COPENHAGEN, Denmark, April 4, 2022 — Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies.
COPENHAGEN, Denmark, December 21, 2021 – Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions. Under the terms of the agreement, Vipergen
COPENHAGEN, Denmark, November 23, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that
